Prosonix and Mylan Enter Into Global Licensing Agreement for Generic Versions of Inhaled Respiratory Products Flixotide® and Flovent®

15-04-2014 14:00

OXFORD, UK, and PITTSBURGH, April 15, 2014 – Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, today announced that it has entered into a global licensing agreement with Mylan Inc. (Nasdaq: MYL), one of the world’s leading global pharmaceutical companies, for its leading inhaled respiratory products, PSX1001 and PSX1050.

PDF-file 331.7kb